Register for free to listen to this article
Listen with Speechify
0:00
2:00
CAMBRIDGE, Mass.—Personal genomics company Knome recently announced it is partnering with Shenzhen, China-based  Beijing Genomics Institute to sequence the entire genomes of two private individuals. These clients are expected to be the first individuals in the world to have their genome sequenced by a personal genomics firm. The announcement coincides with another effort dubbed the 1000 Genomes Project, in which BGI is also participating (see story "Consortium to tackle genome research project", this issue).
 
To date, only three scientists have had their genomes sequenced, all as part of sponsored research efforts. These include Nobel Prize winner Dr. James Watson, Dr. Craig Venter and an anonymous Chinese scientist sequenced by BGI. Once the sequencing for these two most recent commercial clients is finished, Knome and BGI are expected to have completed the sequencing of three of the five known human genomes.
 
"These individuals are pioneering an emerging science with us," says George Church, a co-founder of the firm and professor of genetics at Harvard Medical School. "Whole genome sequencing represents the future of personalized medicine and these sequenced genomes will nearly double the amount of whole-genome information available today."
 
Once the sequencing for these two most recent commercial clients is finished, Knome and BGI are expected to have completed the sequencing of three of the five known human genomes.
 
Knome's whole-genome sequencing and analysis services are being marketed globally to private individuals. Knome is currently offering a limited number of clients the opportunity to participate in its 2008 sequencing programs. Pricing starts at $350,000 and includes both sequencing and a comprehensive analysis from a team of leading geneticists, clinicians and bioinformaticians.
 
"We are very happy to be underway with our first clients," adds Ari Kiirikki, vice president of sales and business development at Knome. "At this time, both clients have chosen to remain anonymous. As part of our service, we have developed a variety of processes and tools designed to keep their genomic identity private and secure. If they choose to release their identity or share their genetic code, it will be on their own terms."

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue